Drug name - Oxlumo

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(7 years from now)

US11060093 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US10465195 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US10487330 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US9828606 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10612027 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10478500 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Oct, 2035

(13 years from now)

CN102006890A ALNYLAM PHARMS INC Targeting Lipid
Oct, 2015

(6 years ago)

CN108064154A ALNYLAM PHARMS INC Composition And Method For Inhibiting Hao1 (Hydroxy Acid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

CN108064154B ALNYLAM PHARMS INC Composition And Method For Inhibiting Expression Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene
Oct, 2035

(13 years from now)

IN372206B ALNYLAM PHARMS INC Double-Stranded Rnai Agents And Compositions For Inhibiting Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

IN201747014263A ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

EP2231195B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP3156077A1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194A2 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP3156077B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194B1 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP2231195A2 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP3087184A1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3087184B1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3087184A4 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3581654A1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3581654B1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3204015A4 ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

EP3204015A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

EP3204015B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA Dec, 2034

(12 years from now)

Drugs and Companies using LUMASIRAN SODIUM ingredient

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.